Efficacy of Dotinurad in Patients with Severe Renal Dysfunction

Overview

Journal Clin Exp Nephrol

Publisher Springer

Specialty Nephrology

Date 2023 Oct 21

PMID 37864678

Authors

Osamu Kurihara

Takehisa Yamada

Katsuhito Kato

Yasushi Miyauchi

Affiliations

Soon will be listed here.

Abstract

Background: Although hyperuricemia is associated with the progression of chronic kidney disease (CKD), a reduction in CKD progression by uric acid (UA)-lowering therapy has been controversial. Recently, dotinurad, a uricosuric drug with selective urate reabsorption inhibitory properties, has been developed. However, its efficacy in lowering serum UA levels and its effects on renal function in patients with severe renal dysfunction are unclear. Thus, this study aimed to determine the effects of dotinurad on renal function in patients with severe renal dysfunction.

Methods: Data from 53 outpatients with hyperuricemia who newly received dotinurad between December 2020 and October 2022 were retrospectively analyzed. The mean baseline estimated glomerular filtration rate (eGFR) was 38.7 ± 17.0 mL/min/1.73 m. The patients were divided into three groups based on their baseline eGFR: eGFR < 30 (n = 17), 30 ≤ eGFR < 45 (n = 17), and eGFR ≥ 45 (n = 19).

Results: The mean follow-up period was 9.8 ± 4.5 (range, 3-21) months. Serum UA levels significantly decreased in all groups. Although eGFR did not significantly change in patients with 30 ≤ eGFR < 45 and eGFR ≥ 45 (P = 0.918 and P = 0.535, respectively), it improved significantly in patients with eGFR < 30 (P = 0.032). The proportion of patients with improved eGFR was significantly higher in patients with eGFR < 30 (P = 0.038) than in patients with 30 ≤ eGFR < 45 and eGFR ≥ 45. In the multivariate logistic regression analysis, baseline eGFR < 30 and achieving a serum UA level of ≤ 6.0 mg/dL were significantly associated with improved eGFR (P = 0.033 and P = 0.015, respectively).

Conclusions: Dotinurad may have UA-lowering effects and the potential to improve kidney function in patients with severe renal dysfunction.

Citing Articles

Comparative assessment of the effects of dotinurad and febuxostat on the renal function in chronic kidney disease patients with hyperuricemia.

Takata T, Taniguchi S, Mae Y, Kageyama K, Fujino Y, Iyama T Sci Rep. 2025; 15(1):8990.

PMID: 40089552 DOI: 10.1038/s41598-025-94020-2.

A Possible Therapeutic Application of the Selective Inhibitor of Urate Transporter 1, Dotinurad, for Metabolic Syndrome, Chronic Kidney Disease, and Cardiovascular Disease.

Yanai H, Adachi H, Hakoshima M, Iida S, Katsuyama H Cells. 2024; 13(5.

PMID: 38474414 PMC: 10931163. DOI: 10.3390/cells13050450.

References

Chen J, Chuang S, Chen H, Yeh W, Pan W . Serum uric acid level as an independent risk factor for all-cause, cardiovascular, and ischemic stroke mortality: a Chinese cohort study. Arthritis Rheum. 2009; 61(2):225-32. DOI: 10.1002/art.24164. View

Storhaug H, Norvik J, Toft I, Eriksen B, Lochen M, Zykova S . Uric acid is a risk factor for ischemic stroke and all-cause mortality in the general population: a gender specific analysis from The Tromsø Study. BMC Cardiovasc Disord. 2013; 13:115. PMC: 4029378. DOI: 10.1186/1471-2261-13-115. View

Bos M, Koudstaal P, Hofman A, Witteman J, Breteler M . Uric acid is a risk factor for myocardial infarction and stroke: the Rotterdam study. Stroke. 2006; 37(6):1503-7. DOI: 10.1161/01.STR.0000221716.55088.d4. View

Zhu P, Liu Y, Han L, Xu G, Ran J . Serum uric acid is associated with incident chronic kidney disease in middle-aged populations: a meta-analysis of 15 cohort studies. PLoS One. 2014; 9(6):e100801. PMC: 4069173. DOI: 10.1371/journal.pone.0100801. View

Kang D, Nakagawa T, Feng L, Watanabe S, Han L, Mazzali M . A role for uric acid in the progression of renal disease. J Am Soc Nephrol. 2002; 13(12):2888-97. DOI: 10.1097/01.asn.0000034910.58454.fd. View

Rosolowsky E, Ficociello L, Maselli N, Niewczas M, Binns A, Roshan B . High-normal serum uric acid is associated with impaired glomerular filtration rate in nonproteinuric patients with type 1 diabetes. Clin J Am Soc Nephrol. 2008; 3(3):706-13. PMC: 2386694. DOI: 10.2215/CJN.04271007. View

Doria A, Galecki A, Spino C, Pop-Busui R, Cherney D, Lingvay I . Serum Urate Lowering with Allopurinol and Kidney Function in Type 1 Diabetes. N Engl J Med. 2020; 382(26):2493-2503. PMC: 7375708. DOI: 10.1056/NEJMoa1916624. View

Badve S, Pascoe E, Tiku A, Boudville N, Brown F, Cass A . Effects of Allopurinol on the Progression of Chronic Kidney Disease. N Engl J Med. 2020; 382(26):2504-2513. DOI: 10.1056/NEJMoa1915833. View

Kimura K, Hosoya T, Uchida S, Inaba M, Makino H, Maruyama S . Febuxostat Therapy for Patients With Stage 3 CKD and Asymptomatic Hyperuricemia: A Randomized Trial. Am J Kidney Dis. 2018; 72(6):798-810. DOI: 10.1053/j.ajkd.2018.06.028. View

10.

Krishnan E, Kwoh C, Schumacher H, Kuller L . Hyperuricemia and incidence of hypertension among men without metabolic syndrome. Hypertension. 2006; 49(2):298-303. DOI: 10.1161/01.HYP.0000254480.64564.b6. View

11.

Chobanian A, Bakris G, Black H, Cushman W, Green L, Izzo Jr J . The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003; 289(19):2560-72. DOI: 10.1001/jama.289.19.2560. View

12.

Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K . Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009; 53(6):982-92. DOI: 10.1053/j.ajkd.2008.12.034. View

13.

Grams M, Sang Y, Ballew S, Matsushita K, Astor B, Carrero J . Evaluating Glomerular Filtration Rate Slope as a Surrogate End Point for ESKD in Clinical Trials: An Individual Participant Meta-Analysis of Observational Data. J Am Soc Nephrol. 2019; 30(9):1746-1755. PMC: 6727262. DOI: 10.1681/ASN.2019010008. View

14.

Takahashi T, Beppu T, Hidaka Y, Hosoya T . Comparative study of a novel selective urate reabsorption inhibitor "dotinurad" among patient groups with different stages of renal dysfunction. Clin Exp Nephrol. 2021; 25(12):1336-1345. PMC: 8526486. DOI: 10.1007/s10157-021-02115-7. View

15.

Farquhar H, Vargas-Santos A, Pisaniello H, Fisher M, Hill C, Gaffo A . Efficacy and safety of urate-lowering therapy in people with kidney impairment: a GCAN-initiated literature review. Rheumatol Adv Pract. 2021; 5(1):rkaa073. PMC: 7819867. DOI: 10.1093/rap/rkaa073. View

16.

Kohagura K, Kochi M, Miyagi T, Kinjyo T, Maehara Y, Nagahama K . An association between uric acid levels and renal arteriolopathy in chronic kidney disease: a biopsy-based study. Hypertens Res. 2012; 36(1):43-9. DOI: 10.1038/hr.2012.135. View

17.

Taniguchi T, Ashizawa N, Matsumoto K, Saito R, Motoki K, Sakai M . Pharmacological Evaluation of Dotinurad, a Selective Urate Reabsorption Inhibitor. J Pharmacol Exp Ther. 2019; 371(1):162-170. DOI: 10.1124/jpet.119.259341. View

18.

Takada T, Yamamoto T, Matsuo H, Tan J, Ooyama K, Sakiyama M . Identification of ABCG2 as an Exporter of Uremic Toxin Indoxyl Sulfate in Mice and as a Crucial Factor Influencing CKD Progression. Sci Rep. 2018; 8(1):11147. PMC: 6057959. DOI: 10.1038/s41598-018-29208-w. View

19.

Miyata H, Takada T, Toyoda Y, Matsuo H, Ichida K, Suzuki H . Identification of Febuxostat as a New Strong ABCG2 Inhibitor: Potential Applications and Risks in Clinical Situations. Front Pharmacol. 2017; 7:518. PMC: 5187494. DOI: 10.3389/fphar.2016.00518. View

20.

Sezai A, Soma M, Nakata K, Hata M, Yoshitake I, Wakui S . Comparison of febuxostat and allopurinol for hyperuricemia in cardiac surgery patients (NU-FLASH Trial). Circ J. 2013; 77(8):2043-9. DOI: 10.1253/circj.cj-13-0082. View